CALL TO ACTION
DNDi’s 4th Partners’ meeting took place this year in Rio, Brazil, on Dec. 2nd. DNDi’s progress in bringing new treatments to neglected patients was reviewed and the main challenges in access to new tools were evaluated, resulting in a Call to Action. More
CHAGAS DISEASE
DNDi recently started recruiting patients for three new clinical studies on diagnosis and treatment of Chagas disease in Argentina and Bolivia. More
LEISHMANIASIS
SSG&PM, a new shorter course, cost-effective treatment for visceral leishmaniasis, is recommended by the WHO as first-line treatment in East Africa. Implementation has commenced in Sudan and South Sudan. More
MALARIA
100 million treatments of ASAQ, DNDi’s antimalarial combination therapy of Artesunate and Amodiaquine, have been distributed in 31 countries since its launch in 2007 ! More
PAEDIATRIC HIV
MSF podcast: ''Children with HIV need more treatment options; DNDi aims to help fill the void.'' More
SLEEPING SICKNESS
SCYX-7158, a drug candidate from the oxaboroles chemical class, will soon enter clinical development. It is the first new oral drug candidate discovered specifically to combat human African trypanosomiasis! More
SCYNEXIS Inc. as part of the DNDi HAT Lead Optimization Consortium
Screening and optimization of specific chemical series against human African Trypanosomiasis (HAT): 4926 compounds
DNDi Lead Optimization Consortium (Epichem, Murdoch University, CDCO):
Optimization of fenarimol series for the treatment of Chagas disease: 751 compounds
PORTFOLIO
Current portfolio:Working in partnership with industry and academia, DNDi has built the largest ever R&D portfolio for the kinetoplastid diseases.
New disease areas:
DNDi has decided to take on two new mini-portfolios: paediatric HIV and helminth infections.
PUBLICATIONS
DNDi model: status and challenges"Drugs for Neglected Diseases initiative model of drug development for neglected diseases: current status and future challenges" by Shing Chang and Jean-Robert Ioset Future Medicinal Chemistry. 2011 September
Paediatric HIV: A neglected disease?
"Pediatric HIV - A Neglected Disease?" by Lallemant M et al. The New England Journal of Medicine. 2011 August
Novel drug candidate for HAT
"SCYX-7158, an Orally-Active Benzoxaborole for the Treatment of Stage 2 Human African Trypanosomiasis" by Jacobs R.T et al. PLoS NTD. 2011 June
R&D for helminth infections
"Potential Drug Development Candidates for Human Soil-Transmitted Helminthiases" by Olliaro P et al. PLoS NTD. 2011 June
Dec 4-8, 2011
60th ASTMH
Philadelphia, USA
DNDi team participated with presentations on Leishmaniasis East Africa Platform and on Chagas disease, as well as with several posters and a DNDi booth.
Dec 2, 2011
DNDi Partners' Meeting 2011
Rio de Janeiro, Brazil
DNDi brought together over 260 health researchers, policy makers, and experts to stimulate greater regional research partnership to fight the most neglected diseases.
Oct 23-26, 2011
World Health Summit
Berlin, Germany
DNDi co-organized a session on Product Development for Neglected Patients and took part to the Innovation session
Oct 3-6, 2011
7th European Congress of Tropical Medicine and Hygiene
Barcelona, Spain
DNDi have had a strong participation at ECTMIH with 1 symposium on kinetoplatids, 1 on VL-HIV coinfection, and many oral presentations and posters
Oct 9-12, 2011
6th EDCTP Forum
Addis Ababa, Ethiopia
DNDi will attend the forum whose theme is this year "Strengthening Research Partnerships for Better Health and Sustainable Development"
DNDI NEWS
DNDi in the Media
Except where otherwise noted, content on this site is licensed under
a Creative Commons Attribution-Noncommercial-Share Alike 2.5 Switzerland License